Missed a GLP-1 Dose? What the FDA Label Actually Says

There is no single "GLP-1 missed dose rule." The most-repeated line online — "you have five days" — is only what one of these labels says. Ozempic's FDA label publishes a 5-day window. Mounjaro's and Zepbound's publish 4 days (96 hours). Wegovy's injection label publishes something different again: give the missed dose only if the next scheduled dose is more than 2 days away. And semaglutide now also comes as a daily tablet (Rybelsus, Wegovy tablets, and Ozempic tablets), where the rule is simply to skip it. Past its own window, every one of these labels drops the missed dose and resumes the normal schedule. Not one of them tells anybody to double up.

What follows is a reference to what the published FDA labels say — not an instruction about what you should do. The person who decides what you do is your prescriber or pharmacist, and for a missed dose they can usually decide it in a two-minute phone call.

The two things every label agrees on, before anything else:
1. Do not take two doses to catch up. No GLP-1 label contains that instruction. The tirzepatide labels forbid it in as many words.
2. Do not re-titrate yourself. Do not raise your dose to "get back on track," and do not drop to a lower pen on your own. Changing a dose is a prescription-level decision.

What each label actually publishes

These are the current US prescribing information texts, read off DailyMed (the NIH's official label archive) on 13 July 2026. Quotation marks mean the words are the label's own.

Check which product you actually have before you use the table

Semaglutide is now sold under one brand name in two completely different forms. Ozempic exists as a weekly injection and as a daily tablet, and those two share a name but not a missed-dose rule: the injection has a 5-day window, the tablet is simply skipped. Wegovy is the same — injection and tablet, different rules. Look at the box in front of you, not at the brand name in your head.

Why Ozempic and Wegovy do not agree with each other

They are the same molecule and they still do not carry the same missed-dose instruction, because the two labels measure from different points. Ozempic's is anchored to the missed dose: was it within the last 5 days? Wegovy's is anchored to the next one: is it more than 2 days away? Someone on Wegovy who is five days late, with their normal injection day now two days out, is in a spot the Ozempic label would call fine and the Wegovy label says to leave alone. Most blog posts and telehealth FAQs flatten both drugs into "the 5-day rule." That is not what the Wegovy label says, and the gap between the two matters at exactly the moment you are anxiously counting days.

Rule 1: do not double up to catch up

No GLP-1 label contains an instruction to take two doses because one was missed. The tirzepatide labels rule it out explicitly — "Do not take 2 doses of MOUNJARO within 3 days of each other," and the same sentence, with "(72 hours)" spelled out, on Zepbound. Ozempic's label sets a floor of at least 2 days (more than 48 hours) between any two doses. A missed dose is not a debt you repay. It either fits inside the label's window or it is gone, and one skipped weekly injection does not undo months of treatment.

The reason the labels are strict about this is that a GLP-1 overdose is a real event with a real clinical picture, not a theoretical concern. Wegovy's OVERDOSAGE section states: "Overdoses have been reported with other GLP-1 receptor agonists. Effects have included severe nausea, severe vomiting, and severe hypoglycemia." Every one of these labels tells clinicians managing an overdose to consider calling the Poison Help line, 1-800-222-1222, and warns that observation may have to be prolonged because the drug hangs around: semaglutide's half-life is about 1 week, tirzepatide's about 5 days. There is no way to flush an excess dose out.

The FDA has documented what dosing errors do in practice. In an alert current as of 26 July 2024, it reported "adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products" — patients drawing the wrong amount from a vial, clinicians miscalculating doses. The reported harms were gastrointestinal effects (nausea, vomiting, abdominal pain), fainting, headache, migraine, dehydration, acute pancreatitis and gallstones. That alert is about compounded vials rather than pens, but the mechanism it describes — more drug in the body than intended — is the same one you create by stacking two weekly doses.

Rule 2: do not re-titrate yourself, in either direction

Dose escalation on these drugs exists for one reason, and the labels say so out loud: to reduce the risk of gastrointestinal adverse reactions. Every step up is a deliberate, timed decision, and so is every step down. Nudging your own dose up because you missed a week and want to make up ground, or quietly switching to a lower-strength pen still sitting in the fridge, converts a supervised titration into an unsupervised experiment. If your dose needs to change, that is a prescription-level change, and it belongs to the person who wrote the prescription. Our breakdowns of the published escalation schedules — Ozempic, Wegovy, Mounjaro, Zepbound — exist so you can follow the conversation with your prescriber, not so you can run it yourself.

What happens after several missed weeks

This is the situation the internet handles worst and the one that actually sends people to urgent care. It is usually not forgetfulness. It is a prior authorization that lapsed, a pharmacy that could not fill, a price that jumped, a trip that ran long.

The tolerance you built during titration is not a permanent upgrade. It is an adaptation to continuous exposure, and it fades once the exposure stops. The labels imply as much by the way they handle restarts: Wegovy's is explicit that "if 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions." A label does not tell prescribers to walk a patient back down for no reason. Injecting the dose you were comfortable on before a long gap, into a body that has lost that accommodation, is a well-trodden route to severe nausea, vomiting and dehydration.

Clearance takes longer than people assume, which cuts both ways. Ozempic's label notes that with a half-life of roughly a week, "semaglutide will be present in the circulation for about 5 weeks after the last dose." So one skipped injection does not empty you out — but a multi-week gap does, and the restart after it is a genuine clinical decision. (What a longer stop does to appetite and weight is a separate question, covered in what happens when you stop a GLP-1.)

Wegovy's own patient leaflet gives the instruction the other labels leave unwritten: "If you miss doses of WEGOVY for 2 or more consecutive weeks, contact your healthcare provider to talk about how to restart your treatment." The Ozempic, Mounjaro and Zepbound labels do not print an equivalent sentence. That silence is not permission — it means the restart plan is left to the prescriber.

So the honest answer to "I missed three weeks, what dose do I restart at?" is: we cannot tell you, and neither can anyone who has not seen your chart. It depends on how long the gap was, what dose you were on, how you tolerated it, why it stopped, and what else you take. It is a clinical decision, it is frequently a lower dose than the one you left off at, and it gets made in a phone call or a portal message — not by you, and not by an article.

The message to send, already worded

If you can get one message to your prescriber or pharmacist, send this:

"I'm on [drug] [dose] mg, [weekly/daily]. My last dose was [date], so I have missed [number] doses. Do I take a dose now or wait for my next scheduled day — and do you want me to restart at a lower dose?"

Four facts, one question. Pharmacists field this call constantly and can usually answer it without an appointment. If your prescriber is a telehealth clinic, this doubles as a test of the clinic: a service that cannot get you a clinician's answer to a missed-dose question inside a day is not really providing care. If you are weighing one up, we walk through how to judge it in how to choose GLP-1 care online.

When the gap is really about money or coverage

A large share of "missed doses" are missed refills. If that is you, the point to take from the section above is that a coverage-driven gap is a clinical event, not just an administrative one — because of the tolerance problem. Tell your prescriber it is coming before it becomes a three-week hole. They can often act: a prior authorization, an appeal of a denial, a formulary alternative, a different pen size, or a documented pause with a planned lower-dose restart. What they cannot do is fix a gap they never heard about.

We deliberately print no price on this page. List prices, manufacturer self-pay programs and plan formularies have each moved more than once in the past year, and a stale number here would be worse than none. Start from what your plan covers — GLP-1 insurance coverage — and check the current numbers for Ozempic, Wegovy and Zepbound on the day you need the answer.

Talk to your prescriber — and when it is urgent

Call your prescriber or pharmacist rather than guessing whenever:

• You have missed one dose and you are not sure which product you have or which window its label describes.
• You have missed two or more consecutive weekly doses, for any reason. This is the restart conversation, and it often means starting lower.
• You are about to run out because of a prior authorization, a pharmacy shortage or cost — tell them before the gap, not after.
• You took a dose too close to the previous one, or took the wrong strength.
• You want to move your injection day. The labels allow it but set a minimum interval, and your prescriber can sequence it safely.

Seek urgent medical care — do not wait for a callback — if you develop vomiting or diarrhea persistent enough that you cannot keep fluids down; severe abdominal pain, particularly pain that radiates to the back (a possible sign of pancreatitis); signs of dehydration such as dizziness on standing or passing very little urine; or symptoms of low blood sugar, which matter most if you also take insulin or a sulfonylurea. If you have accidentally taken an extra or double dose and you feel ill, that is a reason to call a clinician or the Poison Help line (1-800-222-1222) — the number the labels themselves give — not a reason to ride it out.

The one-line version

Your label gives your product a window; once it closes, the missed dose is gone, and you never repay it with a second injection. Everything past that — what you restart at, whether you re-titrate, when you move your injection day — belongs to your prescriber. Bring them the date of your last dose and let them do the arithmetic.

Related reading: how GLP-1 dosing schedules are structured, Ozempic and Wegovy side effects, tirzepatide side effects, Wegovy vs Ozempic, and our drug reference page for semaglutide.

Disclosure: VidaBeacon may earn a commission if you use some of the care links on this site. It does not change what we write, and no company paid for a mention on this page. We name no telehealth provider as a recommendation here.

This page is a reference to publicly published FDA labeling. It is not medical advice, and nothing on it is an instruction to take, skip, adjust, restart or stop a dose. Your prescriber sets your dose.